Return to homepagePandemic Pact

Therapeutic approach]

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Known Financial Commitments (USD)

    $244,000

  • Funder

    Other funders (France)

  • Principal Investigator

    Jérome ESTAQUIER

  • Research Location

    France

  • Lead Research Institution

    Université Paris-Descartes

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The COVID-I2A therapy project aims to highlight biomarkers in patients that predict severe inflammation and damage to lung cells. It also aims to test the efficacy of new compounds, in association with an immunomodulatory molecule of interest, on these two consequences of infection, namely inflammation and cell damage, as well as on virus replication.